Dynamic analysis of pulsed cisplatin identifies effectors of resistance in lung adenocarcinoma
Authors:
- Jordan F. HastingsJHJordan F. Hastings
- Alvaro Gonzalez-RajalAGAlvaro Gonzalez-Rajal
- Jeremy Z.R. HanJHJeremy Z.R. Han
- Rachael A. McCloyRMRachael A. McCloy
- Yolande E.I. O’donnellYOYolande E.I. O’donnell
- Monica PhimmachanhMPMonica Phimmachanh
- Alexander D. MurphyAMAlexander D. Murphy
- Adnan NagrialANAdnan Nagrial
- Dariush DaneshvarDDDariush Daneshvar
- Venessa ChinVCVenessa Chin
- D. Neil WatkinsDWD. Neil Watkins
- Andrew BurgessABAndrew Burgess
Preprint
Abstract
Identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely recapitulates the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA damage and apoptotic responses across a panel of lung adenocarcinoma cell lines. By coupling this data with real-time, single cell imaging of cell cycle and apoptosis, we show that TP53 mutation status influenced the mode of cisplatin induced cell cycle arrest, but could not predict cisplatin sensitivity. In contrast, P70S6K-mediated signalling promoted resistance by increasing p53/p63 and p21 expression, reducing double-stranded DNA breaks and apoptosis. Targeting P70S6K sensitised both TP53 wildtype and null lines to cisplatin, but not TP53 mutant lines. In summary, using in vitro assays that mimic in vivo pharmacokinetics identified P70S6K as a robust mediator of cisplatin resistance and highlighted the importance of considering somatic mutation status when designing patient-specific combination therapies.Keywords
All Related Versions
- Published version: eLife, 9.
This publication has 38 references indexed in Scilit:
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLCPLOS ONE, 2011
- Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop PhosphorylationJournal of Biological Chemistry, 2010
- Cisplatin nephrotoxicity: Mechanisms and renoprotective strategiesKidney International, 2008
- Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle ProgressionCell, 2008
- mTOR and P70 S6 Kinase Expression in Primary Liver NeoplasmsClinical Cancer Research, 2004
- Structure, Recognition, and Processing of Cisplatin−DNA AdductsChemical Reviews, 1999
- Pharmacokinetics of Cisplatin and Its Monohydrated Complex in HumansJournal of Pharmaceutical Sciences, 1996
- p70s6k function is essential for G1 progressionNature, 1993